

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF Art Unit: 1647

Jacques BOLLEKENS et al.

Examiner: Christine J. SAOUD

INTERNATION APPLICATION NO: PCT/EP2004/012572

FILED: 5 November 2004

U.S. APPLICATION NO.: 10/578,470

FILED: 18 April 2008

FOR: Use of Fibroblast Growth Factor Fragments

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

**SUBMISSION OF REPLACEMENT SEQUENCE LISTING**  
**INCLUDING STATEMENT OF VERIFICATION**

Sir:

Applicants hereby provide a Replacement Computer Readable Form (CRF) of the Sequence Listing as well as the Replacement Paper Copy thereof. The undersigned states that the Replacement Paper Copy and the Replacement Computer Readable Form (CRF), submitted in accordance with 37 CFR §1.821(c) and (e), respectively, are the same, and include no new matter.

Respectfully submitted,

Novartis Institutes for BioMedical Research, Inc.  
220 Massachusetts Avenue  
Cambridge, MA 02139  
(617) 871-5077

/ Frank Wu /  
Frank Wu  
Agent for Applicants  
Reg. No. 41,386

Date: 18 November 2010